Fasudil and its analogs: A new powerful weapon in the long war against central nervous system disorders?

Expert Opinion on Investigational Drugs

Volumn 22, Issue 4, 2013, Pages 537-550

  Chen, Meihui ^a   Liu, Anmin ^b   Ouyang, Ying ^b   Huang, Yingjuan ^a   Chao, Xiaojuan ^a   Pi, Rongbiao ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Analogs; Central nervous system disorders; Fasudil; Rho kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; H 1152P; HYDROXYFASUDIL; ISOQUINOLINE DERIVATIVE; METHYLPREDNISOLONE; NIMODIPINE; OZAGREL; RHO KINASE; RHO KINASE INHIBITOR; SLX 2119; UNCLASSIFIED DRUG; Y 39983;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICAL STRUCTURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; EPILEPSY; EVIDENCE BASED MEDICINE; GLAUCOMA; HUMAN; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NEUROPROTECTION; NOCICEPTIVE PAIN; NONHUMAN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; RAYNAUD PHENOMENON; SPINAL CORD INJURY; STRUCTURE ACTIVITY RELATION; SUBARACHNOID HEMORRHAGE; UNSPECIFIED SIDE EFFECT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

EID: 84875184048     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.778242     Document Type: Article

References (98)

1. Raad M, El Tal T, Gul R, et al. Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. Electrophoresis 2012;33(24):3659-68
2. Youdim MB. Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's diseases as disease modifying agents. Exp Neurobiol 2010;19(1):1-14
3. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 2004;116(2):167-79
4. Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci 2010;67(2):171-7
5. Leung T, Chen XQ, Manser E, et al. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16(10):5313-27
6. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996;15(9):2208-16
7. Kubo T, Yamaguchi A, Iwata N, et al. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther Clin Risk Manag 2008;4(3):605-15
8. Jeon BT, Jeong EA, Park SY, et al. The Rho-Kinase (ROCK) inhibitor Y-27632 protects against excitotoxicity-induced neuronal death in vivo and in vitro. Neurotox Res 2012. [Epub ahead of print]
9. Ding J, Yu JZ, Li QY, et al. Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF. Brain Behav Immun 2009;23(8):1083-8
10. Couch BA, DeMarco GJ, Gourley SL, et al. Increased dendrite branching in AbetaPP/PS1 mice and elongation of dendrite arbors by fasudil administration. J Alzheimers Dis 2010;20(4):1003-8
11. Iizuka M, Kimura K, Wang S, et al. Distinct distribution and localization of Rho-kinase in mouse epithelial, muscle and neural tissues. Cell Struct Funct 2012;37(2):155-75
12. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev 1997;11(18):2295-322
13. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005;6(2):167-80
14. Dong M, Yan BP, Liao JK, et al. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today 2010;15(15-16):622-9
15. Yamashita K, Kotani Y, Nakajima Y, et al. Fasudil, a Rho kinase (ROCK) inhibitor, protects against ischemic neuronal damage in vitro and in vivo by acting directly on neurons. Brain Res 2007;1154:215-24
16. Satoh N, Toyohira Y, Itoh H, et al. Stimulation of norepinephrine transporter function by fasudil, a Rho kinase inhibitor, in cultured bovine adrenal medullary cells. Naunyn Schmiedebergs Arch Pharmacol 2012;385(9):921-31
17. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006;290(3):C661-8
18. Surma M, Wei L, Shi J. Rho kinase as a therapeutic target in cardiovascular disease. Future Cardiol 2011;7(5):657-71
19. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996;15(8):1885-93
20. Chang J, Xie M, Shah VR, et al. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci USA 2006;103(39):14495-500
21. Sebbagh M, Renvoize C, Hamelin J, et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 2001;3(4):346-52
22. Sumi T, Matsumoto K, Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J Biol Chem 2001;276(1):670-6
23. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rhokinase). Science 1996;273(5272):245-8
24. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4(6):446-56
25. Lin T, Zeng L, Liu Y, et al. Rho-ROCK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element binding proteins. Circ Res 2003;92(12):1296-304
26. Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 1999;147(5):1023-38
27. Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392(2):189-93
28. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4(5):387-98
29. Tawara S, Shimokawa H. Progress of the study of rho-kinase and future perspective of the inhibitor. Yakugaku Zasshi 2007;127(3):501-14
30. Manintveld OC, Verdouw PD, Duncker DJ. The RISK of ROCK. Am J Physiol Heart Circ Physiol 2007;292(6):H2563-5
31. Rikitake Y, Oyama N, Wang CY, et al. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/-haploinsufficient mice. Circulation 2005;112(19):2959-65
32. Thumkeo D, Keel J, Ishizaki T, et al. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 2003;23(14):5043-55
33. Zhang YM, Bo J, Taffet GE, et al. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J 2006;20(7):916-25
34. Shimizu Y, Thumkeo D, Keel J, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 2005;168(6):941-53
35. Thumkeo D, Shimizu Y, Sakamoto S, et al. ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells 2005;10(8):825-34
36. Shi J, Wei L. Rho kinase in the regulation of cell death and survival. Arch Immunol Ther Exp (Warsz) 2007;55(2):61-75
37. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011;301(2):H287-96
38. Boerma M, Fu Q, Wang J, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul Fibrinolysis 2008;19(7):709-18
39. Ishida T, Takanashi Y, Kiwada H. Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biol Pharm Bull 2006;29(3):397-402
40. Zhao CH, Liu YP, Wang X, et al. The absorption and distribution of fasudil hydrochloride in the rat. J Shenyang Pharm Univ 2011;28(11):906-11
41. Zhao YD, Cai L, Mirza MK, et al. Protein kinase G-I deficiency induces pulmonary hypertension through Rho A/Rho kinase activation. Am J Pathol 2012;180(6):2268-75
42. Chen H, Lin Y, Han M, et al. Simultaneous quantitative analysis of fasudil and its active metabolite in human plasma by liquid chromatography electro-spray tandem mass spectrometry. J Pharm Biomed Anal 2010;52(2):242-8
43. Han ML. Synthesis of fasudil and its analogues. [Master Degree] Tianjin University; Tianjin: 2009
44. Disli OM, Ozdemir E, Berkan O, et al. Rho-kinase inhibitors Y-27632 and fasudil prevent agonist-induced vasospasm in human radial artery. Can J Physiol Pharmacol 2009;87(8):595-601
45. Shibuya M, Suzuki Y, Takayasu M, et al. The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs. Acta Neurochir (Wien) 1988;90(1-2):53-9
46. Wang QM, Stalker TJ, Gong Y, et al. Inhibition of Rho-kinase attenuates endothelial-leukocyte interaction during ischemia-reperfusion injury. Vasc Med 2012;17(6):379-85
47. Chiba Y, Kuroda S, Shichinohe H, et al. Synergistic effects of bone marrow stromal cells and a Rho kinase (ROCK) inhibitor, fasudil on axon regeneration in rat spinal cord injury. Neuropathology 2010;30(3):241-50
48. Nakabayashi S, Nagaoka T, Tani T, et al. Retinal arteriolar responses to acute severe elevation in systemic blood pressure in cats: role of endothelium-derived factors. Exp Eye Res 2012;103:63-70
49. Tsounapi P, Saito M, Kitatani K, et al. Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensive rats. Eur J Pharmacol 2012;691(1-3):182-9
50. Schinzari F, Tesauro M, Rovella V, et al. Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome. Am J Physiol Endocrinol Metab 2012;303(6):E806-11
51. Price WH, Steers AJ, Wilson J. Subarachnoid hemorrhage and Klinefelter's syndrome. Lancet 1982;2(8294):380
52. Zhao J, Zhou D, Guo J, et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurol Med Chir (Tokyo) 2011;51(10):679-83
53. Hao SJ, An HJ. Efficacy of hydrochloric acid fasudil for vasospasm after subarachnoid hemorrhage. J Shanxi Med Univ 2012;43(04):290-2
54. Satoh S, Takayasu M, Kawasaki K, et al. Antivasospastic effects of hydroxyfasudil, a Rho-kinase inhibitor, after subarachnoid hemorrhage. J Pharmacol Sci 2012;118(1):92-8
55. Nakamura T, Matsui T, Hosono A, et al. Beneficial effect of selective intra-arterial infusion of fasudil hydrochloride as a treatment of symptomatic vasospasm following SAH. Acta Neurochir Suppl 2013;115:81-5
56. Olson MF. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008;20(2):242-8
57. Broussalis E, Killer M, McCoy M, et al. Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. Drug Discov Today 2012;17(7-8):296-309
58. Wang QM, Stalker TJ, Gong Y, et al. Inhibition of Rho kinase attenuates endothelial-leukocyte interaction during ischemic-reperfusion injury. Vasc Med 2012;17(6):379-85
59. Dobkin BH, Havton LA. Basic advances and new avenues in therapy of spinal cord injury. Annu Rev Med 2004;55:255-82
60. McDonald JW, Sadowsky C. Spinal-cord injury. Lancet 2002;359(9304):417-25
61. Hara M, Takayasu M, Watanabe K, et al. Protein kinase inhibition by fasudil hydrochloride promotes neurological recovery after spinal cord injury in rats. J Neurosurg 2000;93(1 Suppl):94-101
62. Baba H, Tanoue Y, Maeda T, et al. Protective effects of cold spinoplegia with fasudil against ischemic spinal cord injury in rabbits. J Vasc Surg 2010;51(2):445-52
63. Impellizzeri D, Mazzon E, Paterniti I, et al. Effect of Fasudil, a selective inhibitor of Rho Kinase activity, in the secondary injury associated with the experimental model of spinal cord trauma. J Pharmacol Exp Ther 2012;343(1):21-33
64. Sung JK, Miao L, Calvert JW, et al. A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat. Brain Res 2003;959(1):29-38
65. Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet 2011;377(9770):1019-31
66. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004;5(9):677-85
67. Hou Y, Zhou L, Yang QD, et al. Changes in hippocampal synapses and learning-memory abilities in a streptozotocin-treated rat model and intervention by using fasudil hydrochloride. Neuroscience 2012;200:120-9
68. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011;10(5):377-93
69. Tonges L, Frank T, Tatenhorst L, et al. Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain 2012;135(Pt 11):3355-70
70. Villar-Cheda B, Dominguez-Meijide A, Joglar B, et al. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 2012;47(2):268-79
71. Grau JW, Huie JR, Garraway SM, et al. Impact of behavioral control on the processing of nociceptive stimulation. Front Physiol 2012;3:262
72. Ahn DK, Lee SY, Han SR, et al. Intratrigeminal ganglionic injection of LPA causes neuropathic pain-like behavior and demyelination in rats. Pain 2009;146(1-2):114-20
73. Boyce-Rustay JM, Simler GH, McGaraughty S, et al. Characterization of Fasudil in preclinical models of pain. J Pain 2010;11(10):941-9
74. Tatsumi S, Mabuchi T, Katano T, et al. Involvement of Rho-kinase in inflammatory and neuropathic pain through phosphorylation of myristoylated alanine-rich C-kinase substrate (MARCKS). Neuroscience 2005;131(2):491-8
75. Marcos Z. Xavier Montalban: a pioneer in understanding multiple sclerosis. Lancet Neurol 2012;11(10):846
76. Sun X, Minohara M, Kikuchi H, et al. The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis. J Neuroimmunol 2006;180(1-2):126-34
77. Yu JZ, Ding J, Ma CG, et al. Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor. J Neurosci Res 2010;88(8):1664-72
78. Hou SW, Liu CY, Li YH, et al. Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect. CNS Neurosci Ther 2012;18(11):909-17
79. LoGrasso PV, Feng Y. Rho kinase (ROCK) inhibitors and their application to inflammatory disorders. Curr Top Med Chem 2009;9(8):704-23
80. Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42(6):796-803
81. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46(4):470-2
82. Inan S, Buyukafsar K. Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice. Br J Pharmacol 2008;155(1):44-51
83. Breitenlechner C, Gassel M, Hidaka H, et al. Protein kinase A in complex with Rho-kinase inhibitors Y-27632, Fasudil, and H-1152P: structural basis of selectivity. Structure 2003;11(12):1595-607
84. Lavogina D, Kalind K, Bredihhina J, et al. Conjugates of 5-isoquinolinesulfonylamides and oligo-D-arginine possess high affinity and selectivity towards Rho kinase (ROCK). Bioorg Med Chem Lett 2012;22(10):3425-30
85. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002;93(2-3):225-32
86. Tamura M, Nakao H, Yoshizaki H, et al. Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta 2005;1754(1-2):245-52
87. Ray P, Wright J, Adam J, et al. Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors. Bioorg Med Chem Lett 2011;21(4):1084-8
88. Iwakubo M, Takami A, Okada Y, et al. Design and synthesis of rho kinase inhibitors (III). Bioorg Med Chem 2007;15(2):1022-33
89. Enkvist E, Lavogina D, Raidaru G, et al. Conjugation of adenosine and hexa-(Darginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J Med Chem 2006;49(24):7150-9
90. Geldenhuys WJ, Van der Schyf CJ. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders. Expert Opin Drug Discov 2013;8(2):115-29
91. Chiang L, Jones MR, Ferreira CL, et al. Multifunctional ligands in medicinal inorganic chemistry-current trends and future directions. Curr Top Med Chem 2012;12(3):122-44
92. Koumura A, Hamanaka J, Kawasaki K, et al. Fasudil and ozagrel in combination show neuroprotective effects on cerebral infarction after murine middle cerebral artery occlusion. J Pharmacol Exp Ther 2011;338(1):337-44
93. Nakashima S, Tabuchi K, Shimokawa S, et al. Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 1998;38(12):805-10
94. Suzuki Y, Shibuya M, Satoh S, et al. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 2008;48(6):241-7
95. Lapchak PA, Han MK. Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. Brain Res 2010;1344:217-25
96. Ishiguro M, Kawasaki K, Suzuki Y, et al. A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator. Neuroscience 2012;220:302-12
97. Takeshima H, Kobayashi N, KoguchiW, et al. Cardioprotective effect of a combination of Rho-kinase inhibitor and p38MAPK inhibitor on cardiovascular remodeling and oxidative stress in Dahl rats. J Atheroscler Thromb 2012;19(4):326-36
98. Takeda Y, Nishikimi T, Akimoto K, et al. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Hypertens Res 2010;33(9):965-73